New blood test

Reducing unnecessary ovarian cancer surgery

The majority of women who undergo surgery for suspected ovarian cancer do not have cancer. A novel blood test developed by researchers at Uppsala University and the Sahlgrenska Academy, University of Gothenburg, now offers the possibility of more precise diagnostics without the need for surgery.

Source: Shutterstock/Nerthuz

This could lead to a reduction in unnecessary surgery and to earlier detection and treatment for affected women. The study was recently published in Communications Biology. Ovarian cancer is often discovered at a late stage and has a high mortality rate. Out of 10 patients, only 3–4 survive 5 years after treatment, and there has been no test specific enough to justify screening. Women with accidental findings of an ovarian cyst or with symptoms instead undergo ultrasound and if abnormalities are seen, surgery is the only way to make sure all cancers are detected. This means that many women are operated on without having cancer, resulting in unnecessary surgery and increased risks for women.

I see great prospects of developing a strategy for screening for ovarian cancer as well, which could save lives and minimise the need for surgery to rule out cancer

Ulf Gyllensten

“We need to develop more accurate pre-surgery diagnostics. To detect one cancer, we operate on up to five women – yet this is currently the best option when abnormalities are detected by ultrasound and cancer is suspected. There is a great need for a simple blood test that could identify women who do not need surgery,” says Karin Sundfeldt, Professor and Senior Consultant at the Department of Obstetrics and Gynecology, Institute of Clinical Sciences at Sahlgrenska Academy, University of Gothenburg.

In the published study, the researchers have developed a biomarker test based on analysis of 11 proteins. The test, which is performed on a blood sample, is used where ultrasound has indicated abnormalities to identify women without cancer. For cases in which physicians chose to operate, the cancer rate could increase from one in five to one in three. This would greatly reduce unnecessary surgery and the risk of complications related to surgery.

Recommended article

The biomarker profile can also detect borderline cases and early stages of the disease. “Our results are promising enough to consider screening for early discovery of ovarian cancer. In Sweden, we have long experience of screening for cervical cancer. I see great prospects of developing a strategy for screening for ovarian cancer as well, which could save lives and minimise the need for surgery to rule out cancer,” says Ulf Gyllensten, Professor of Medical Molecular Genetics at the Department of Immunology, Genetics and Pathology at Uppsala University.

The paper, published in the open access journal Communications Biology (Springer Nature Publishing AG), presents a new test that has been developed in collaboration with Uppsala-based biotech company Olink Proteomics AB. “We are now continuing to evaluate the test and are performing a large-scale study of samples collected at all hospitals from the western region and Halland healthcare system,” says Gyllensten.


Source: Uppsala University

27.06.2019

Read all latest stories

Related articles

Photo

Digital pathology

AI delivers cervical cancer screening to rural areas of Kenya

Experts from Sweden, Finland and Kenya are using digital microscopy combined with Artificial Intelligence (AI) to deliver a rapid and effective cervical screening service to rural locations in Kenya.…

Photo

HPV testing advances

Cervical cancer screening: Emerging tech to replace Pap smears

Emerging technologies can screen for cervical cancer better than Pap smears and, if widely used, could save lives both in developing nations and parts of countries, like the United States, where…

Photo

Oncology breakthrough

Blood test detects 50+ cancer types, often before symptoms show

Researchers have developed the first blood test that can accurately detect more than 50 types of cancer and identify in which tissue the cancer originated, often before there are any clinical signs…

Related products

Alsachim, a Shimadzu group company – Dosinaco

Clinical Chemistry

Alsachim, a Shimadzu group company – Dosinaco

Alsachim, a Shimadzu Group Company
ASP Lab Automation – Recapper KapSafe

Sample Processing

ASP Lab Automation – Recapper KapSafe

ASP Lab Automation AG
ASP Lab Automation – Tube Sorter SortPro

Sample Processing

ASP Lab Automation – Tube Sorter SortPro

ASP Lab Automation AG
Beckman Coulter – DxA 5000

Sample Processing

Beckman Coulter – DxA 5000

Beckman Coulter, Inc.
FUJIFILM Wako - Autokit CH50 Assay

Clinical Chemistry

FUJIFILM Wako - Autokit CH50 Assay

Wako Chemicals GmbH
Fujifilm Wako – Autokit Total Ketone Bodies Assay

Clinical Chemistry

Fujifilm Wako – Autokit Total Ketone Bodies Assay

FUJIFILM Wako Chemicals Europe GmbH
Subscribe to Newsletter